Enhancing natural killer cells is beneficial in multiple sclerosis

Abstract

Get full access to this article

View all access options for this article.

References

Caligiuri

MA.

Human natural killer cells. Blood 2008; 112: 461–469.

Cooper

Fehniger

Turner

et al . Human natural killer cells: A unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001; 97: 3146–3151.

Laroni

Gandhi

Beynon

et al . IL-27 imparts immunoregulatory function to human NK cell subsets. PLoS ONE 2011; 6: e26173.

Morandi

Horenstein

Chillemi

et al . CD56brightCD16– NK cells produce adenosine through a CD38-mediated pathway and act as regulatory cells inhibiting autologous CD4+ T cell proliferation. J Immunol 2015; 195: 965–972.

Laroni

Armentani

de Rosbo

et al . Dysregulation of regulatory CD56(bright) NK cells/T cells interactions in multiple sclerosis. J Autoimmun 2016; 72: 8–18.

Gross

Schulte-Mecklenbeck

Runzi

et al . Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation. Proc Natl Acad Sci U S A 2016; 113: E2973–E2982.

Nielsen

Odum

Urso

et al . Cytotoxicity of CD56(bright) NK cells towards autologous activated CD4+ T cells is mediated through NKG2D, LFA-1 and TRAIL and dampened via CD94/NKG2A. PLoS ONE 2012; 7: e31959.

Fehniger

Cooper

Nuovo

et al . CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: A potential new link between adaptive and innate immunity. Blood 2003; 101: 3052–3057.

Darlington

Stopnicki

Touil

et al . Natural killer cells regulate Th17 cells after autologous hematopoietic stem cell transplantation for relapsing remitting multiple sclerosis. Front Immunol 2018; 9: 834.

10.

Hao

Liu

Piao

et al . Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J Exp Med 2010; 207: 1907–1921.

11.

Saraste

Irjala

Airas

Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol Sci 2007; 28: 121–126.

12.

Gross

Ahmetspahic

Ruck

et al . Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2016; 3: e289.

13.

Bielekova

Catalfamo

Reichert-Scrivner

et al . Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A 2006; 103: 5941–5946.

14.

Rauer

Stork

Urbach

et al . Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy. Neurology 2018; 91: e359–1e63.

15.

Ikizawa

et al . Regulation of activated CD4+ T cells by NK cells via the Qa-1-NKG2A inhibitory pathway. Immunity 2007; 26: 593–604.

16.

Liu

Sanai

Jin

et al . Neural stem cells sustain natural killer cells that dictate recovery from brain inflammation. Nat Neurosci 2016; 19: 243–252.

Enhancing natural killer cells is beneficial in multiple sclerosis – Yes

Abstract

Get full access to this article

References